JNJ-73841937, JNJ-61186372
61186372NSC2012
Phase 2 small_molecule active
Quick answer
JNJ-73841937, JNJ-61186372 for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active